Procter & Gamble shares currently trade slightly above our estimated intrinsic value of $122.63, leading us to maintain a Hold recommendation. At 20.5 times trailing earnings and 23 times free cash flow, the stock’s valuation multiples remain elevated relative to its projected growth. While the company’s wide economic moat and consistent cash generation support a premium multiple, upside appears limited unless management can accelerate top-line expansion or unlock further cost synergies.

In Q1 2026, Procter & Gamble delivered 3% organic revenue growth and 21% growth in adjusted EPS, driven by productivity savings and disciplined pricing actions. Core beauty, health and home care segments each posted mid‐single-digit top-line gains. Management reiterated expectations for low-to-mid single-digit organic sales growth for the full year, with operating margin expansion of 20–30 basis points supported by ongoing supply chain restructuring and SG&A optimization.

Shares recently hit a 52-week low of $137.62 before recovering slightly to close at $138.04, reflecting heightened promotional activity and softer category demand in key markets. Rising input costs, challenging currency dynamics, and consumer discretionary spending pressures in North America and Europe remain key risk factors. Should macroeconomic headwinds intensify, margin expansion targets could be at risk and valuation multiples may re-rate lower.

Procter & Gamble is leveraging cost reduction programs, network rationalization and digital sourcing to drive an annualized productivity benefit of roughly $10 billion by fiscal 2026. The company has delivered 40 consecutive quarters of organic sales growth and maintains a roughly 3% dividend yield, underpinned by a payout ratio below 60%. Continued innovation in core brands and disciplined capital allocation are expected to support mid-single-digit EPS growth over the long term.